Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-029122
Filing Date
2022-08-11
Accepted
2022-08-11 16:11:07
Documents
63
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q achv-10q_20220630.htm   iXBRL 10-Q 2213788
2 EX-31.1 achv-ex311_7.htm EX-31.1 9067
3 EX-32.1 achv-ex321_6.htm EX-32.1 4884
4 GRAPHIC g4iegmpx3mfa000001.jpg GRAPHIC 106007
  Complete submission text file 0001564590-22-029122.txt   7676324

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA achv-20220630.xsd EX-101.SCH 53085
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE achv-20220630_cal.xml EX-101.CAL 38076
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20220630_def.xml EX-101.DEF 197427
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20220630_lab.xml EX-101.LAB 387140
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20220630_pre.xml EX-101.PRE 297455
57 EXTRACTED XBRL INSTANCE DOCUMENT achv-10q_20220630_htm.xml XML 1283097
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 221155841
SIC: 2835 In Vitro & In Vivo Diagnostic Substances